A proof of concept study to evaluate the feasibility of safe and effective treatment through optimization of the Cryo-Touch III device for temporary relief of pain.
Over 100 million patients in the United States suffer from chronic pain. Chronic pain conditions are often debilitating, taking a toll on a patient's physical and mental welfare. Though a variety of pain management techniques currently exist, the most common nonsurgical options provide slow-acting and/or short-term relief. Medication, often in the form of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, comes with an array of side effects such as nausea and vomiting. Medication also presents the possibility of more serious effects such as increased risk of heart attack and stroke, and tolerance or dependency issues. Surgical strategies tend to be reserved for more severe cases and are limited by the risks and complications typically associated with surgery including bleeding, bruising, scarring, and infection. A nonsurgical, minimally invasive, long-lasting approach to chronic pain management is desirable. The Cryo-Touch III is a pain management device developed for a novel, minimally invasive procedure using focused cold therapy to target sensory nerve tissue and offer long-lasting pain relief through cryoanalgesia. The device operates on the well-established cryobiology principle that localized exposure to controlled moderately low temperature conditions can alter tissue function. The therapy treats nerves with low temperatures via a cold probe in the form of an assembly of small diameter needles, creating a highly localized treatment zone around the probe. This focused cold therapy creates a conduction block that prevents nerve signaling. Though studies have proven efficacious in targeting motor nerves, the device's effect on sensory nerves has yet to have been investigated in the clinical setting. The goal of the study described herein is to evaluate the degree and duration of effect of the Cryo-Touch III in reducing chronic pain by targeting sensory nerves.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Study treatment at Day 0.
Neurovations
Napa, California, United States
Injury Care Medical Center
Boise, Idaho, United States
Average Improvement in VAS Pain Score From Baseline to Day 7
Visual Analog Scale(VAS), where a higher score indicates greater intensity; 0= no pain, 10=worst pain
Time frame: Baseline to Day 7
Improvement in WOMAC Index From Baseline to Day 7
The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain scale. A tri-dimensional, disease-specific, patient-reported outcome measure. Consists of 24 questions: 5 pain, 2 stiffness and 17 function. Each category contains a set of questions rated by the Subject on a 0-10 scale; The highest possible score was 50 for pain, 20 for stiffness and 170 for function, based on the 0-10 scale used to assess each question. The total score range is 0 to 240 with higher scores correlating to worse outcomes.
Time frame: Baseline to Day 7
Number of Participants Who Experienced Continued Treatment Effect at Each Time Point
Subjects were asked to report whether they experienced continued treatment effect at the timepoints indicated.
Time frame: Visit 3 (Day 7), Visit 4 (Day 30), Visit 5 (Day 56)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.